Phathom Pharmaceuticals Inc, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, has announced that the US FDA has approved Voquezna (vonoprazan) tablets 10 mg and 20 mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults for the healing of all grades of erosive esophagitis, also known as Erosive GERD (gastroesophageal reflux disease), maintenance of healing of all grades of Erosive GERD, and relief of heartburn associated with erosive GERD.
“This approval demonstrates Phathom's commitment to changing the gastrointestinal treatment landscape for patients and healthcare providers, bringing the first major innovation to the US in erosive GERD market in over 30 years,” said Terrie Curran, president and CEO of Phathom. “Erosive GERD can be extremely painful and often has a significant impact on patients. Research has shown patients and healthcare providers are largely unsatisfied with current treatments and we are excited about the approval of a first-in-class treatment option that has the potential to meet a large unmet medical need.”
Erosive GERD, also referred to as erosive esophagitis or erosive acid reflux, is a major type of GERD that affects approximately 20 million people in the US. In addition to experiencing troubling heartburn symptoms, patients with inadequately treated erosive GERD may develop more severe diseases including Barrett’s esophagus, a condition in which esophageal tissue changes can progress to cancer.
This approval is based on positive results from the phase 3 PHALCON-EE study (NCT04124926). The pivotal trial was a randomized, double-blind, multicenter study that enrolled 1,024 patients with erosive GERD in the US and Europe and compared Voquezna to the PPI lansoprazole in the healing and maintenance of healing of erosive GERD and associated heartburn symptom relief.
Results showed that Voquezna 20 mg met the primary endpoint of non-inferiority (p<0.0001) for complete healing by week 8 in patients with all grades of erosive GERD with a healing rate of 93% compared to 85% for lansoprazole 30 mg, with superior rates of healing demonstrated in a secondary endpoint in patients with moderate-to-severe disease (LA Grade C/D) at week 2 compared to lansoprazole (70% for Voquezna 20 mg and 53% for lansoprazole 30 mg) (p=0.0008). Voquezna 20 mg also demonstrated non-inferiority to lansoprazole 30 mg in the mean percentage of 24-hour heartburn free days over the healing period. In the maintenance phase of the trial, Voquezna 10 mg was superior to lansoprazole 15 mg in maintaining healing at six months in all randomized patients (79% for Voquezna 10 mg, compared to 72% for lansoprazole 15 mg) as well as in the subset of patients with moderate-to-severe erosive GERD (75% for Voquezna 10 mg, compared to 61% for lansoprazole 15 mg) (p=0.0490). In addition, Voquezna 10 mg was evaluated as a secondary endpoint for relief of heartburn in erosive GERD patients and demonstrated non-inferiority to lansoprazole 15 mg over six months.
Adverse event rates for Voquezna were comparable to lansoprazole in the trial. The most common AEs in the healing phase (= 2% in the Voquezna treatment arm) were gastritis (3.0% for Voquezna 20 mg and 2.0% for lansoprazole 30 mg), diarrhea (2.0% for Voquezna 20 mg and 3.0% for lansoprazole 30 mg), abdominal distension (2.0% for Voquezna 20 mg and 1.0 % for lansoprazole 30 mg), abdominal pain (2.0% for Voquezna 20 mg and 1.0% for lansoprazole 30 mg) and nausea (2.0% for Voquezna 20 mg and 1.0% for lansoprazole 30 mg). The most common AEs in the maintenance phase (= 3% in the Voquezna treatment arm) for Voquezna 10 mg compared to lansoprazole 15 mg were gastritis (6.0% vs. 3.0%), abdominal pain (4.0% vs. 2.0%), dyspepsia (4.0% vs. 3.0%), hypertension (3.0% vs. 2.0%), and urinary tract infection (3.0% vs. 2.0%). These are not all of the potential side effects associated with the use of Voquezna.
“For many GERD patients with erosive esophagitis, the response to current treatment is suboptimal, leaving them with incomplete healing and ongoing symptoms,” said Colin W. Howden, MD, Professor Emeritus, University of Tennessee College of Medicine. “The FDA approval of Voquezna (vonoprazan) provides healthcare providers with a new first-in-class therapeutic option that demonstrated faster healing in the more difficult to treat GERD patients with erosive esophagitis. In addition, Voquezna (vonoprazan) provided superior maintenance of healing in all grades of erosive esophagitis, compared to lansoprazole, a commonly prescribed PPI, and provided 24-hour heartburn relief on most days in the trial.”
Voquezna is expected to be available in the US in December 2023 and will be marketed exclusively by Phathom Pharmaceuticals, Inc.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!